INT26404

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1989
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 15
Total Number 16
Disease Relevance 10.94
Pain Relevance 4.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (ATM) signal transduction (ATM) cell death (ATM)
cytoplasmic membrane-bounded vesicle (ATM) nucleus (ATM) DNA binding (ATM)
Anatomy Link Frequency
plasma 1
lung 1
RT4 1
ATM (Homo sapiens)
Pain Link Frequency Relevance Heat
cva 93 100.00 Very High Very High Very High
qutenza 21 99.98 Very High Very High Very High
Oxycodone 4 99.98 Very High Very High Very High
depression 2 97.72 Very High Very High Very High
Hippocampus 17 93.60 High High
nMDA receptor 12 93.20 High High
MU agonist 1 89.20 High High
aspirin 16 87.52 High High
agonist 12 85.92 High High
antagonist 4 85.28 High High
Disease Link Frequency Relevance Heat
Chronic Lymphoid Leukemia 142 100.00 Very High Very High Very High
Thrombosis 69 100.00 Very High Very High Very High
Telangiectasia 6 100.00 Very High Very High Very High
Disease 284 99.84 Very High Very High Very High
Ataxia 10 99.66 Very High Very High Very High
Lung Cancer 3 99.42 Very High Very High Very High
Cancer 190 99.12 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 32 99.08 Very High Very High Very High
Colon Cancer 192 98.62 Very High Very High Very High
Malignant Neoplastic Disease 11 98.36 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Oxycodone elevated plasma prolactin at 1.5 and 3 hr while growth hormone levels remained unaffected.
Positive_regulation (elevated) of at 1 in plasma associated with oxycodone
1) Confidence 0.49 Published 1989 Journal Pharmacol. Toxicol. Section Abstract Doc Link 2555803 Disease Relevance 0.10 Pain Relevance 0.72
Two tumor suppressor genes that are inactivated as a result of common CLL mutations, p53 and ATM, are established causal contributors to malignant transformation.
Positive_regulation (result) of ATM associated with chronic lymphoid leukemia, malignant neoplastic disease and cancer
2) Confidence 0.44 Published 2005 Journal Environ Health Perspect Section Body Doc Link PMC1253701 Disease Relevance 1.07 Pain Relevance 0
Moreover, we observed that CPS activates ATM kinase that is involved in Ser15, Ser20 and Ser392 p53 phosphorylation as shown by the use of the specific inhibitor KU55933.
Positive_regulation (involved) of ATM associated with qutenza
3) Confidence 0.43 Published 2009 Journal Carcinogenesis Section Abstract Doc Link 19502594 Disease Relevance 0.94 Pain Relevance 0.52
Moreover, we observed that CPS activates ATM kinase that is involved in Ser15, Ser20 and Ser392 p53 phosphorylation as shown by the use of the specific inhibitor KU55933.
Positive_regulation (activates) of ATM associated with qutenza
4) Confidence 0.43 Published 2009 Journal Carcinogenesis Section Abstract Doc Link 19502594 Disease Relevance 0.94 Pain Relevance 0.53
Notably, ATM activation was also found to control upregulation of Fas/CD95 expression and its co-clustering with TRPV1 as well as RT4 cell growth and apoptosis.
Positive_regulation (activation) of ATM in RT4 associated with apoptosis
5) Confidence 0.40 Published 2009 Journal Carcinogenesis Section Abstract Doc Link 19502594 Disease Relevance 0.90 Pain Relevance 0.49
In the current report we show that the chromosome binding protein, 53BP1, and the activated DNA damage response kinase, P-ATM, are both significantly elevated in AD cases with Braak stage of V or above.
Positive_regulation (elevated) of P-ATM associated with disease
6) Confidence 0.28 Published 2010 Journal Mol Neurodegener Section Body Doc Link PMC3018387 Disease Relevance 0.72 Pain Relevance 0.08
In the current report we show that the chromosome binding protein, 53BP1, and the activated DNA damage response kinase, P-ATM, are both significantly elevated in AD cases with Braak stage of V or above.
Positive_regulation (activated) of P-ATM associated with disease
7) Confidence 0.28 Published 2010 Journal Mol Neurodegener Section Body Doc Link PMC3018387 Disease Relevance 0.72 Pain Relevance 0.08
It was found that DNA damage inflicted at a low rate failed to activate ATM; however, if ATM was activated by chloroquine, the cells survived the low dose rate much better.
Neg (failed) Positive_regulation (activate) of ATM
8) Confidence 0.22 Published 2006 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC1998878 Disease Relevance 0.09 Pain Relevance 0
It was found that DNA damage inflicted at a low rate failed to activate ATM; however, if ATM was activated by chloroquine, the cells survived the low dose rate much better.
Positive_regulation (activated) of ATM
9) Confidence 0.15 Published 2006 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC1998878 Disease Relevance 0.09 Pain Relevance 0
Lau et al. [28] demonstrated that the ataxia-telangiectasia (ATM) kinase, one of the cellular regulators of responses to DNA damage, is activated by integration of the HIV genome into the host-cell genome.
Positive_regulation (activated) of ATM associated with telangiectasia, ataxia and acquired immune deficiency syndrome or hiv infection
10) Confidence 0.11 Published 2006 Journal Genome Biol Section Body Doc Link PMC1431708 Disease Relevance 1.52 Pain Relevance 0
In summary, patients treated with bevacizumab are at a higher risk of developing ATE, especially patients older then 65 years with previous history of ATE.81,94,95 Although patients above 65 years have a slightly higher risk of ATE, oncologists must assess the risk/benefit of its use, especially as the benefit of bevacizumab is seen across all age groups.
Positive_regulation (risk) of ATE associated with cva
11) Confidence 0.09 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886334 Disease Relevance 1.09 Pain Relevance 0.53
In summary, patients treated with bevacizumab are at a higher risk of developing ATE, especially patients older then 65 years with previous history of ATE.81,94,95 Although patients above 65 years have a slightly higher risk of ATE, oncologists must assess the risk/benefit of its use, especially as the benefit of bevacizumab is seen across all age groups.
Positive_regulation (risk) of ATE associated with cva
12) Confidence 0.09 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886334 Disease Relevance 1.07 Pain Relevance 0.47
Analysis of pooled data from five randomized trials in patients with metastatic CRC, breast, and non-small-cell lung cancer by Scappaticci et al showed increased risk of ATE (HR 2.0, 95% CI 1.05–3.75, p = 0.031) but not VTE (HR 0.89, 95% CI 0.66–1.20, p = 0.44).92 The absolute rate of developing an ATE was 5.5 events per 100 person-years for patients receiving combination therapy versus 3.1 events for patients receiving chemotherapy alone (ratio 1.8, 95% CI 0.94–3.33, p = 0.76).
Positive_regulation (increased) of ATE in lung associated with lung cancer, colon cancer and cva
13) Confidence 0.08 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886334 Disease Relevance 1.65 Pain Relevance 0.58
In mammalian cells, DNA double strand breaks usually result in activation of ATM, whereas ATR is activated in response to UV and stalled replication.
Positive_regulation (activation) of ATM
14) Confidence 0.08 Published 2008 Journal PLoS Genetics Section Body Doc Link PMC2583946 Disease Relevance 0 Pain Relevance 0
ATM is predominantly required for Chk2 activation whereas ATR is predominantly required for Chk1 activation, although there is some cross talk between the pathways (reviewed in [54]–[56]).
Positive_regulation (required) of ATM
15) Confidence 0.05 Published 2008 Journal PLoS Genetics Section Body Doc Link PMC2583946 Disease Relevance 0 Pain Relevance 0
This receptor consists of a large extracellular part which comprises the ATD and ABD, and which displays a twofold axis of symmetry.
Positive_regulation (comprises) of ATD
16) Confidence 0.03 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989583 Disease Relevance 0.05 Pain Relevance 0.38

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox